tradingkey.logo

Revvity's Q4 revenue, adjusted EPS rise on diagnostics growth

ReutersFeb 2, 2026 11:09 AM


Overview

  • Health science solutions provider's Q4 revenue grew 6% yr/yr to $772 mln

  • Adjusted EPS for Q4 rose to $1.70 from $1.42 yr/yr

  • Company initiates full year 2026 guidance, forecasting revenue of $2.96-$2.99 bln


Outlook

  • Revvity forecasts 2026 revenue between $2.96 bln and $2.99 bln

  • Company expects 2026 organic revenue growth of 2-3%

  • Revvity projects 2026 adjusted EPS of $5.35-$5.45


Result Drivers

  • DIAGNOSTICS GROWTH - Diagnostics segment revenue increased 10%, with 7% organic growth, aiding overall revenue growth

  • LIFE SCIENCES PERFORMANCE - Life Sciences segment showed 2% revenue growth, but organic revenue was flat

  • PORTFOLIO TRANSFORMATION - CEO cited portfolio transformation as positioning the company to capitalize on market conditions


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 EPS

$0.87

Q4 Adjusted EPS continuing operations

$1.70


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Revvity Inc is $115.00, about 5.7% above its January 30 closing price of $108.80

  • The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nBwkQl67a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI